KRAS and non-small cell lung carcinoma: Gefitinib disrupts K-Ras/PI3K and K-Ras/Raf complexes in human non-small cell lung cancer (NSCLC) Calu3 cells but not in K-Ras-mutant Calu3ras cells [7, 30].